Ars Pharmaceuticals, Inc. (SPRY)
NASDAQ:SPRY
Want to see SPRY full AI Analyst Report?
SPRY Stock Chart & Stats
$8.30
-$0.02(-0.18%)
At close: 4:00 PM EST
$8.30
-$0.02(-0.18%)
Day’s Range― - ―
52-Week Range$6.66 - $18.90
Previous CloseN/A
Volume456.05K
Average Volume (3M)1.52M
Market Cap
$820.20M
Enterprise Value$834.14M
Total Cash (Recent Filing)$244.99M
Total Debt (Recent Filing)$96.96M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
May 19, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding99,297,310
10 Day Avg. Volume1,149,847
30 Day Avg. Volume1,522,577
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)10.05
Price to Sales (P/S)13.63
P/FCF Ratio-6.71
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.90
Enterprise Value/Gross Profit13.06
Enterprise Value/Ebitda-4.87
Forecast
1Y Price Target
$27.50Price Target Upside231.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.52
Revenue Forecast (FY)$157.52M
Bulls Say, Bears Say
Bulls Say
Commercial Execution And MarketingSalesforce expansion funded by resource reallocation, together with direct-to-consumer advertising and virtual prescribing programs, should boost prescriber engagement and patient demand, supporting prescription growth.
Product Label And UsabilityFDA label updates permitting sniffing during administration and use after thawing enhance real-world usability and increase the likelihood patients carry and can administer the device when needed.
Regulatory Approval (Canada)Health Canada approval makes neffy the first needle-free epinephrine option in Canada, expanding access and creating a new commercial market opportunity.
Bears Say
Commercial Payer AccessInsufficient formulary placement with commercial payers remains a key barrier to prescribing and could limit market penetration until major payer contracts are secured.
Medicaid Coverage RiskLimited Medicaid adoption across states could restrict reimbursement for many patients and slow uptake in public payer markets.
Seasonal Demand And Operational HeadwindsOperational headwinds that previously limited capitalization on peak seasonal demand could recur and dampen sales momentum during future high-demand periods.
ARS Pharmaceuticals News
SPRY FAQ
What was Ars Pharmaceuticals, Inc.’s price range in the past 12 months?
Ars Pharmaceuticals, Inc. lowest stock price was $6.66 and its highest was $18.90 in the past 12 months.
What is Ars Pharmaceuticals, Inc.’s market cap?
Ars Pharmaceuticals, Inc.’s market cap is $820.20M.
When is Ars Pharmaceuticals, Inc.’s upcoming earnings report date?
Ars Pharmaceuticals, Inc.’s upcoming earnings report date is May 19, 2026 which is in 16 days.
How were Ars Pharmaceuticals, Inc.’s earnings last quarter?
Ars Pharmaceuticals, Inc. released its earnings results on Mar 09, 2026. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.02.
Is Ars Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Ars Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Ars Pharmaceuticals, Inc. pay dividends?
Ars Pharmaceuticals, Inc. does not currently pay dividends.
What is Ars Pharmaceuticals, Inc.’s EPS estimate?
Ars Pharmaceuticals, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Ars Pharmaceuticals, Inc. have?
Ars Pharmaceuticals, Inc. has 99,297,310 shares outstanding.
What happened to Ars Pharmaceuticals, Inc.’s price movement after its last earnings report?
Ars Pharmaceuticals, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -0.11%.
Which hedge fund is a major shareholder of Ars Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SPRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ARS Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.50 (231.33% Upside)
$27.50 (231.33% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 47.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.02%
12-Months-Change
Fundamentals
Return on Equity
-100.29%
Trailing 12-Months
Asset Growth
-6.69%
Trailing 12-Months
Company Description
Ars Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
SPRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed solid early commercial traction and meaningful operational progress: first full-year net product revenue of $72.2M, strong aided awareness gains (20% to 60%), >22,500 prescribers with 50% repeat writers, a $245M cash runway, and encouraging real-world effectiveness data (~90% single-dose success). However, growth is constrained by structural market dynamics (refill dominance, e-prescribing, prior authorization), a high gross-to-net impact (~low- to mid-50% range), and substantial SG&A spending ($230.1M) relative to current product revenue. Management outlined concrete mitigation actions—salesforce expansion funded via reallocation, continued DTC/digital conversion (getneffy.com ~10% of scripts), and ongoing payer negotiations—that suggest a pathway to steadier growth and eventual refill-driven renewals in late 2026–2027. Overall, positives around adoption, awareness, cash sufficiency, and product performance slightly outweigh the near-term commercialization and margin headwinds.View all SPRY earnings summariesSPRY Stock 12 Month Forecast
Average Price Target
$27.50
▲(231.33% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Pharming Group
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
59.91% Insiders
8.30% Mutual Funds
1.22% Other Institutional Investors
21.31% Public Companies and
Individual Investors